Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is positioned for potential success with its two TYK2 inhibitors, envudeucitinib and A-005, due to their promising clinical data and potential for treating a wide range of diseases, including psoriasis and lupus. The company's recent announcement to file an NDA for envudeucitinib in psoriasis in the fourth quarter of 2026 is a positive sign for investors and could lead to potential market approval and revenue growth. The company's financials, including a price target of $40 based on probability-adjusted modeling and a strong pipeline of potential catalysts, suggest a positive outlook on the stock's potential. However, the company will face competition from other oral treatments and will need to provide clear clinical advantages for its drugs to stand out in the market.

Bears say

Alumis is facing significant commercialization risks as its potential target indications and products may not be as large as projected due to competitive pressures from other oral therapies and lower-than-expected switching from marketed products. The company's two TYK2 inhibitors may face challenges in terms of market penetration and commercialization due to the dominance of approved biologics in the systemic targeted therapies market for psoriasis and SLE, as well as the established presence of large pharmaceutical companies. The stock has a negative valuation due to potential regulatory risks and the company's need to prove that its products, specifically envudeucitinib in psoriasis, can compete in a crowded and challenging market.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.